Apollo Hospitals Group announced plans to expand its network of Genomics Institutes—currently operational in 12 cities—to five additional locations in the coming months. The rollout will include Tier-2 centres such as Guwahati, Bhubaneswar, and Indore, with the aim of improving access to genomic testing beyond metro hubs where awareness and availability remain limited.
So far, Apollo has conducted over 11,000 genomic consultations spanning cancer, reproductive health, rare genetic disorders, and preventive care. With a team of more than 30 trained geneticists and counsellors, the group is positioning genomics as a core pillar of precision medicine in India.
Affordability will be a major focus of this expansion. Currently, whole genome sequencing costs around ₹60,000, but Apollo projects that as testing technology advances, volumes increase, and turnaround times shorten, the price could fall to below ₹20,000 within the next three years. This drop would make personalised diagnostics accessible to a much wider patient base.
“Reaching more than 11,000 genomic consultations underscores the impact of integrating genetic insights into mainstream care. We are committed to making genomic testing accessible and integral to standard healthcare,” said Preetha Reddy, Vice-Chairperson of Apollo Hospitals.
This expansion reinforces Apollo’s long-term strategy of embedding genomics-driven precision medicine into mainstream healthcare while making advanced diagnostics both affordable and accessible across India.